+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
8 Apr 2018

US FDA approval of Sonoma Pharma’s antimicrobial post-therapy gel

/
Posted By
/
Comments0
/

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, has received a new 510(k) clearance from the US Food and Drug Administration (FDA) for an antimicrobial post-therapy gel. Under the supervision of a healthcare professional, the new product is intended for the management of post-non-ablative laser therapy procedures and post-microdermabrasion therapy as well for use following superficial chemical peels. It may also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns.

As briefed by the company – “This antimicrobial post-treatment gel is a promising new tool for all dermatologists and aesthetic clinicians who are looking to better manage medical procedures, post-procedure itch and pain associated with procedures including laser skin resurfacing, while promoting enhanced healing and protection against secondary infections. In our clinical testing to date, we have seen dramatically improved outcomes with quicker healing times and less patient discomfort when this advanced technology is added to our procedure management protocol.”

Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for management of dermatological conditions and advanced tissue care.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.